Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Pharmacognosy MagazineNOW IN
    Article

    Syringin Protects against Cerebral Ischemia and Reperfusion Injury via Suppression of Inflammatory Mediators and Toll‑Like Receptor/MyD88 Signaling Pathway in Rats

    Yihong Huang1★, Xiaopeng Wang1★, Shaobing Guan1, Han Lin1, Zhizhong Mei1, Zhi Huang3★★ Corresponding author

    1. 1Department of Neurology, The Affiliated Dongguan Houjie Hospital of Guangdong Medical University, Dongguan, Guangdong 523945, China.
    2. 2Department of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
    3. 3Department of Neurology, Liuyang Hospital of Traditional Chinese Medicine, Liuyang, Hunan 410300, China.

    CORRESPONDENCE

    Yihong Huang

    Department of Neurology, The Affiliated Dongguan Houjie Hospital of Guangdong Medical University, Dongguan, Guangdong 523945, China.

    huangzhi19123@sina.com

    Received: 26-02-2021; Revised: 13-05-2021; Accepted: 26-07-2021.

    Volume 18, Issue 77 · pp. 168–174 · PUBLISHED 28 March 2022 · DOI: 10.4103/pm.pm_98_21

    View on Pharmacogn. Mag. original site ↗

    ABSTRACT

    Objectives: In this research work, we envisioned to observe the neuroprotective actions of syringin against ischemic‑reperfusion (I/R)‑provoked ischemic stroke in rats. Materials and Methods: The focal cerebral I/R injuries were roused to the male Wistar rats through the middle coronary artery occlusion (MCAO) technique. The syringin (10, 25, and 50 mg/kg) was administered to the rats through intragastric route for 7 successive days prior to MCAO and another 3 days after MCAO. Sham rats were administered with usual diet. The neurological score and parameters were measured by standard methods. The status of inflammatory cytokines and mediators in both serum and brain tissues was considered by commercial assay kits. The mRNA expression of toll‑like receptor (TLR) 4, MyD88, Fas, and FasL was inspected by reverse transcription–polymerase chain reaction technique. Results: The syringin administration to I/R rats established the lessened neurological score and parameters. Syringin supplementation was meritoriously suppressed the levels of the inflammatory cytokine, i.e., interleukin (IL)‑1 β, IL‑6, and tumor necrosis factor‑α and enhanced the IL‑10 status in I/R rats. Syringin abridged the inflammatory mediators like cyclooxygenase‑2, prostaglandin‑2, and nuclear factor kappa B levels in the serum and brain tissues. The mRNA expression of TLR4, MyD88, Fas, and FasL was noticeably downregulated by the syringin. Conclusion: Taken together, our results showed the curative role of syringin against ischemic stroke in rats. Syringin can be an auspicious anti‑stroke agent in future to treat ischemic stroke.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Huang, Y., Wang, X., Guan, S., Lin, H., Mei, Z., & Huang, Z. (2022). Syringin Protects against Cerebral Ischemia and Reperfusion Injury via Suppression of Inflammatory Mediators and Toll‑Like Receptor/MyD88 Signaling Pathway in Rats. Pharmacognosy Magazine, 18(77), 168–174. https://doi.org/10.4103/pm.pm_98_21